Panchsheel Organics Limited

BSE:531726 Stock Report

Market Cap: ₹2.7b

Panchsheel Organics Valuation

Is 531726 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 531726 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 531726 (₹228.15) is trading above our estimate of fair value (₹58.82)

Significantly Below Fair Value: 531726 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 531726?

Key metric: As 531726 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 531726. This is calculated by dividing 531726's market cap by their current earnings.
What is 531726's PE Ratio?
PE Ratio18.9x
Earnings₹142.50m
Market Cap₹2.69b

Price to Earnings Ratio vs Peers

How does 531726's PE Ratio compare to its peers?

The above table shows the PE ratio for 531726 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average84.4x
539730 Fredun Pharmaceuticals
18.8xn/a₹3.3b
531569 Sanjivani Paranteral
49.8xn/a₹3.4b
524654 Natural Capsules
139.9xn/a₹3.0b
530163 Kerala Ayurveda
129.1xn/a₹3.7b
531726 Panchsheel Organics
18.9xn/a₹2.7b

Price-To-Earnings vs Peers: 531726 is good value based on its Price-To-Earnings Ratio (18.9x) compared to the peer average (84.4x).

Price to Earnings Ratio vs Industry

How does 531726's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.5xn/aUS$67.74m
524652 Ind-Swift
2xn/aUS$13.11m
No more companies available in this PE range
531726 18.9xIndustry Avg. 34.2xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 531726 is good value based on its Price-To-Earnings Ratio (18.9x) compared to the Indian Pharmaceuticals industry average (34.2x).

Price to Earnings Ratio vs Fair Ratio

What is 531726's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

531726 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531726's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹143.0b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,196.05

7D

0.8%

1Y

-22.8%

Colinz Laboratories

₹134.8m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.10

7D

3.0%

1Y

37.2%